IOVA (Iovance Biotherapeutics) Tariff Resilience Score: 8/10 (As of Jun. 29, 2026)


IOVA Iovance Biotherapeutics Inc IOVA
44 GF Score
Price $4.23
GF Value $18.84
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Tariff Resilience Score?

Iovance Biotherapeutics IOVA +1.07% 44 Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.84 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,376 Biotechnology companies, Iovance Biotherapeutics ranks better than 98.69% on this metric.

Iovance Biotherapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Iovance Biotherapeutics has Iovance's focus on the U.S. market and its biotech nature provide some insulation from tariffs. While it relies on global suppliers, its innovative products offer pricing flexibility to offset tariff costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Iovance Biotherapeutics might have Highly Resilient.

Iovance Biotherapeutics  (NAS:IOVA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Iovance Biotherapeutics Tariff Resilience Score Related Terms

IOVA vs SNDX, GLUE, TYRA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Tariff Resilience Score falls into.


IOVA
44GF Score
Iovance Biotherapeutics Inc IOVA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Iovance Biotherapeutics (IOVA) has a Tariff Resilience Score of 8 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Iovance Biotherapeutics ranks #18 out of 1376 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Iovance Biotherapeutics' Tariff Resilience Score too high?
Iovance Biotherapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Iovance Biotherapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #18 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Tariff Resilience Score compare to SNDX and GLUE?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #18 out of 1376 companies for Tariff Resilience Score. This places Iovance Biotherapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Iovance Biotherapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.84, compared to a current price of $4.23 — trading 77.5% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of $4.23 is trading 77.5% below its estimated GF Value™ of $18.84. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for IOVA:

  • Tariff Resilience Score: 8
  • GF Value™: $18.84 vs. price of $4.23 (77.5% below fair value)
  • GF Score™: 44/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1376)

No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for IOVA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.23
Price
$18.84
GF Value